BR112012026480A2 - combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída - Google Patents

combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída

Info

Publication number
BR112012026480A2
BR112012026480A2 BR112012026480A BR112012026480A BR112012026480A2 BR 112012026480 A2 BR112012026480 A2 BR 112012026480A2 BR 112012026480 A BR112012026480 A BR 112012026480A BR 112012026480 A BR112012026480 A BR 112012026480A BR 112012026480 A2 BR112012026480 A2 BR 112012026480A2
Authority
BR
Brazil
Prior art keywords
dihydroimidazo
quinazoline
combinations
component
containing substituted
Prior art date
Application number
BR112012026480A
Other languages
English (en)
Portuguese (pt)
Inventor
Ningshu Liu
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012026480(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of BR112012026480A2 publication Critical patent/BR112012026480A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112012026480A 2010-04-16 2011-04-14 combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída BR112012026480A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
BR112012026480A2 true BR112012026480A2 (pt) 2016-08-16

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026480A BR112012026480A2 (pt) 2010-04-16 2011-04-14 combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída

Country Status (24)

Country Link
US (1) US20130184270A1 (https=)
EP (1) EP2558126A2 (https=)
JP (1) JP5886271B2 (https=)
KR (1) KR20130098155A (https=)
CN (1) CN102958540B (https=)
AU (1) AU2011240003A1 (https=)
BR (1) BR112012026480A2 (https=)
CA (1) CA2796253A1 (https=)
CL (1) CL2012002887A1 (https=)
CO (1) CO6620036A2 (https=)
CR (1) CR20120524A (https=)
CU (1) CU20120150A7 (https=)
DO (1) DOP2012000269A (https=)
EA (1) EA201201414A8 (https=)
EC (1) ECSP12012261A (https=)
IL (1) IL222356A0 (https=)
MA (1) MA34158B1 (https=)
MX (1) MX2012012064A (https=)
PE (1) PE20130191A1 (https=)
PH (1) PH12012502069A1 (https=)
SG (1) SG184550A1 (https=)
TN (1) TN2012000493A1 (https=)
WO (1) WO2011128407A2 (https=)
ZA (1) ZA201208616B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
MX2015014171A (es) 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
AU2016231260A1 (en) * 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
CA3016584A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
UA82205C2 (en) * 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
MX2008002114A (es) * 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
US8808742B2 (en) * 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
WO2011128407A2 (en) 2011-10-20
CN102958540A (zh) 2013-03-06
US20130184270A1 (en) 2013-07-18
EA201201414A8 (ru) 2013-12-30
WO2011128407A3 (en) 2012-02-23
ZA201208616B (en) 2015-08-26
EA201201414A1 (ru) 2013-04-30
IL222356A0 (en) 2012-12-31
CO6620036A2 (es) 2013-02-15
SG184550A1 (en) 2012-11-29
CU20120150A7 (es) 2013-02-26
PE20130191A1 (es) 2013-02-21
WO2011128407A9 (en) 2011-12-22
JP2013525293A (ja) 2013-06-20
TN2012000493A1 (en) 2014-04-01
AU2011240003A1 (en) 2012-11-08
KR20130098155A (ko) 2013-09-04
ECSP12012261A (es) 2012-11-30
DOP2012000269A (es) 2012-12-15
MX2012012064A (es) 2012-12-17
CL2012002887A1 (es) 2013-01-18
HK1182937A1 (en) 2013-12-13
EP2558126A2 (en) 2013-02-20
JP5886271B2 (ja) 2016-03-16
PH12012502069A1 (en) 2013-02-04
MA34158B1 (fr) 2013-04-03
CN102958540B (zh) 2015-09-02
CR20120524A (es) 2013-01-09
CA2796253A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
BR112012026480A2 (pt) combinações contendo 2,3-di-hidroimidazo[1,2-c]quinazolina substituída
MX2013003695A (es) Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
BR112017019188A2 (pt) Combinações contendo 2,3-di-hidroimidazo[1,2-c] quinazolina substituídas
UA109698C2 (xx) Похідні азаіндазолу або діазаіндазолу як медикамент
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
CY1123174T1 (el) Φαρμακοτεχνικες μορφες(+)-2-[1-(3-αιθοξυ-4 μεθοξυ-φαινυλ)-2 μεθανοσουλφονυλ-αιθυλ]-4-ακετυλαμινοϊσοϊνδολινο-1,3-διονης
BR112014029016A8 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
BR112012023660B8 (pt) usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer
BR112014001369A2 (pt) derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral
NO20091254L (no) Terapeutiske sammensetninger
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BR112022004099A2 (pt) Composto, composição farmacêutica, uso do composto, e, método para o tratamento de uma doença relacionada ao atx
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112014004732A2 (pt) composto benzotiazolona
BR112014004339A2 (pt) suspensão oral
CL2013003556A1 (es) Compuestos derivados de ftalazinona-pirrolo[3,2-d]pirimidin-carboxamida, inhibidoers de fosfodiesterasa tipo 4 y tipo 5; composcin farmaceutica que o comprende, combinacion fija, no fija y kit, uso del compuesto en la preparacion de un medicamento para trata enfermedaes de las vias respiratorias
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
EA200970086A1 (ru) Азаиндольные производные с сочетанием частичного агонизма к никотиновому ацетилхолиновому рецептору и ингибирования обратного захвата дофамина
BR112016009214A8 (pt) uso de um composto para preparação de um medicamento para o tratamento de distrofia muscular e composição farmacêutica
BR112013025410A2 (pt) tratamento terapêutico
TN2013000141A1 (en) Substituted n-(2-arylamino) aryl sulfonamide-containing combinations
BR112014001751A2 (pt) derivados de pirazolina e seu uso como moduladores seletivos do receptor de estrogênio

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]